GA NCORP

NCORP Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Status
Active
Cancer Type
Hodgkin Lymphoma
Trial Phase
Phase II
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCD ID
NCT01716806
Protocol IDs
SGN35-015 (primary)
Study Sponsor
Seagen Inc.

Summary

This trial will study brentuximab vedotin to find out whether it is an effective treatment
for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study
will be older or will have other conditions that make them unable to have standard
chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with
other drugs.

Objectives

This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as
monotherapy and in combination with other agents as frontline therapy. There are 6 parts of
the study. The population to be studied includes treatment-naïve patients with classical
Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell
lymphoma (PTCL).

Treatment Sites


Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
Northside Hospital Central Research Department
404-303-3355
www.northside.com